| DOR BioPharma Has SPA Clearance From FDA To Start Confirmatory Phase 3 Clinical Trial Of OrBec(R) In GI GVHD (Medical News Today) |
|
|
DOR BioPharma, Inc. (DOR or the Company) (OTCBB: DORB) announced that it has reached agreement with the US Food and Drug Administration (FDA) on the design of a confirmatory, pivotal Phase 3 clinical trial evaluating its lead product orBec(R) for the treatment of acute gastrointestinal Graft-versus-Host Disease (GI GVHD). |